Medicus Pharma (MDCX) grants director 25K stock options at $0.50

Rhea-AI Filing Summary

Medicus Pharma Ltd. director Robert J. Ciaruffoli reported receiving a grant of stock options covering 25,000 underlying Common Shares. The options have a conversion price of $0.50 per share, are exercisable beginning on March 26, 2027, and expire on March 27, 2031. Following this award, he holds 25,000 stock options directly.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Ciaruffoli Robert J.

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	25,000	$0.00	--

Holdings After Transaction: Stock Option (right to buy) — 25,000 shares (Direct)

Footnotes (1)

Key Figures

Options granted: 25,000 options Exercise price: $0.50 per share Exercisable date: March 26, 2027 +2 more

5 metrics

Options granted 25,000 options Stock Option (right to buy) covering 25,000 Common Shares

Exercise price $0.50 per share Conversion or exercise price for the stock options

Exercisable date March 26, 2027 Date from which options may be exercised

Expiration date March 27, 2031 Options expiry for the 25,000-share grant

Total options after grant 25,000 options Total derivative holdings following the reported transaction

Key Terms

Stock Option (right to buy), Grant, award, or other acquisition, Common Shares, total_shares_following_transaction

4 terms

Stock Option (right to buy) financial

"security_title: Stock Option (right to buy)"

Grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

Common Shares financial

"underlying_security_title: Common Shares"

Common shares are the basic units of ownership in a company that give holders a claim on profits and a right to vote on key matters, like electing the board. Think of them as membership cards in a club: they let you share in successes and losses, but in a bankruptcy or liquidation they are paid after creditors and preferred shareholders, so their value can swing more and matters for assessing risk and potential return.

total_shares_following_transaction financial

"total_shares_following_transaction: 25000.0000"

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ciaruffoli Robert J.

(Last) (First) (Middle)

300 CONSHOHOCKEN STATE ROAD

SUITE 200

(Street)

W. CONSHOHOCKEN PENNSYLVANIA 19428

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Medicus Pharma Ltd. [ MDCX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/30/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$0.5	03/30/2026		A		25,000		03/26/2027	03/27/2031	Common Shares	25,000	$0	25,000	D

Explanation of Responses:

	/s/ Raza Bokhari, as Attorney-in-Fact, for Robert J. Ciaruffoli	04/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Medicus Pharma (MDCX) disclose for Robert J. Ciaruffoli?

Medicus Pharma disclosed that director Robert J. Ciaruffoli received a grant of stock options for 25,000 underlying Common Shares. These options were awarded at a conversion price of $0.50 per share and represent a compensation-related acquisition, not an open-market trade.

How many Medicus Pharma (MDCX) options did the director acquire and at what price?

The director acquired stock options over 25,000 underlying Common Shares with a conversion or exercise price of $0.50 per share. This award increases his derivative position to 25,000 options, all held directly according to the reported ownership details.

When can the new Medicus Pharma (MDCX) options be exercised and when do they expire?

The newly granted stock options become exercisable on March 26, 2027. They carry an expiration date of March 27, 2031, giving the director a multi‑year window to convert the options into Common Shares at the stated exercise price of $0.50.

Is the Medicus Pharma (MDCX) Form 4 transaction a buy or a grant?

The Form 4 transaction is classified as a grant or award acquisition, not an open‑market purchase. It is coded “A” for a grant, indicating the director received stock options as compensation rather than buying shares on the market.

What is the director’s option position in Medicus Pharma (MDCX) after this Form 4?

After the reported transaction, the director holds 25,000 stock options directly. Each option is linked to one underlying Common Share and is exercisable at $0.50 per share, based on the total shares following transaction disclosed in the Form 4 data.